Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) and Fate Therapeutics (NASDAQ:FATE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Lakefront Biotherapeutics American Depositary Shares and Fate Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lakefront Biotherapeutics American Depositary Shares | 0 | 5 | 3 | 1 | 2.56 |
| Fate Therapeutics | 1 | 3 | 4 | 0 | 2.38 |
Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $37.00, suggesting a potential upside of 23.75%. Fate Therapeutics has a consensus target price of $5.90, suggesting a potential upside of 229.61%. Given Fate Therapeutics’ higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.
Profitability
This table compares Lakefront Biotherapeutics American Depositary Shares and Fate Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lakefront Biotherapeutics American Depositary Shares | N/A | N/A | N/A |
| Fate Therapeutics | -1,941.09% | -65.08% | -41.73% |
Institutional and Insider Ownership
32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Lakefront Biotherapeutics American Depositary Shares and Fate Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lakefront Biotherapeutics American Depositary Shares | $1.26 billion | 1.57 | $363.05 million | ($1.41) | -21.21 |
| Fate Therapeutics | $6.65 million | 32.25 | -$136.32 million | ($1.05) | -1.70 |
Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Fate Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.
About Lakefront Biotherapeutics American Depositary Shares
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
